Sun Loo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sun Loo has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
- Andrew H. Wei
Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
164 shared publications - Natasha S. Anstee
The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
159 shared publications - Ambrine Sahal
Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France
154 shared publications - Amélie Chedru
15Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, MetaboHUB, Gif sur Yvette, France
154 shared publications - Anne S. Dejean
UMR Inserm, U1043, Toulouse, France
154 shared publications - Antoine Graffeuil
Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France
154 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 3 June 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (7) , 910-913
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia
FLT3-ITD measurable residual disease (MRD) testing for patients in remission from acute myeloid leukemia (AML) is now recommended by the recently updated clinical standard of care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.
- 3 June 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (7) , 910-913
Top Cited PapersOpen AccessELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia
FLT3-ITD measurable residual disease (MRD) testing for patients in remission from acute myeloid leukemia (AML) is now recommended by the recently updated clinical standard of care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.
- Open Access
- 10 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 915-916
FLT3 -ITD MRD in intensive therapy: footprint, not yet the path
- 10 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 915-916
Open AccessFLT3 -ITD MRD in intensive therapy: footprint, not yet the path
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S6: Proteomic analysis of FLT3-ITD AML cell lines treated with vehicle or QUIZ
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S6: Proteomic analysis of FLT3-ITD AML cell lines treated with vehicle or QUIZ
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S4: GSEA results in FLT3-ITD PDX AML cells ex vivo-treated with QUIZ or Veh.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S4: GSEA results in FLT3-ITD PDX AML cells ex vivo-treated with QUIZ or Veh.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S1: Transcriptome analysis of FLT3-ITD cell lines after FLT3 inhbition
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S1: Transcriptome analysis of FLT3-ITD cell lines after FLT3 inhbition
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S2: EnrichR analysis of FLT3 gene signatures
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S2: EnrichR analysis of FLT3 gene signatures
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S10: EnrichR analysis of CEBPA_UP signature
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S10: EnrichR analysis of CEBPA_UP signature
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S13 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S13: lipidomic results by lipid species in dox-inducible and constitutives shRNAs and siRNA CTL/CEBPA, empty vector/CEBPA-OE and vehicle/QUIZ conditions in MOLM-14 cells
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S13 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S13: lipidomic results by lipid species in dox-inducible and constitutives shRNAs and siRNA CTL/CEBPA, empty vector/CEBPA-OE and vehicle/QUIZ conditions in MOLM-14 cells
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S15 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S15: Relative quantification by lipid class
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S15 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Table S15: Relative quantification by lipid class